Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05683223 · ClinicalTrials.gov registry record · NA
Neural Markers of Treatment Mechanisms and Prediction of Treatment Outcomes in Social Anxiety
A NA study of Social Anxiety Disorder, sponsored by Boston University Charles River Campus.
- Recruiting
- Registry status
- NA
- Development phase
- 240
- Enrollment target
- 1
- Study location
NCT05683223 is a NA study of Social Anxiety Disorder that is actively recruiting participants, run by Boston University Charles River Campus. The registered enrollment target is 240 participants, above the 153-participant average among 32 other Social Anxiety Disorder trials with a reported enrollment target (57% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05683223, a NA study of Social Anxiety Disorder, is actively recruiting participants, sponsored by Boston University Charles River Campus.
- RECRUITING
- Registry status
- NA
- Development phase
- 240 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this clinical trial is to answer the question: can the investigators predict which adults with social anxiety disorder (SAD) will successfully respond to treatment? To answer this question, the investigators plan to recruit 190 adult participants who experience extreme forms of social anxiety to undergo brain imaging before and after 12 weeks of group cognitive behavioral therapy (CBT). Adults in the SAD group who do not respond enough to group CBT may be offered the opportunity to complete an additional 12 weeks of individual CBT while receiving SSRI medication (sertraline, see below) for SAD. Data collected from participants who experience anxiety will be compared to a group of 50 participants with little or no social anxiety, who will serve as a comparison group.
Conditions Studied
Interventions
- DRUG Sertraline
- BEHAVIORAL Group CBT for Social Anxiety Disorder
- BEHAVIORAL Individual CBT for Social Anxiety Disorder
Study Locations (1)
Massachusetts
- Center for Anxiety and Related Disorders at Boston University - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2023-05-26 |
| Est. Completion | 2027-06-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05683223
The ClinicalTrials.gov registry entry for NCT05683223 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 153-participant average among 32 other Social Anxiety Disorder trials with a reported enrollment target (57% higher). The listed sponsor is Boston University Charles River Campus, which has 104 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Social Anxiety Disorder appearing as the primary indexed condition, and to 3 interventions - of which Sertraline is the first listed.
NCT05683223 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05683223 about?
NCT05683223 is a clinical study titled "Neural Markers of Treatment Mechanisms and Prediction of Treatment Outcomes in Social Anxiety". The purpose of this clinical trial is to answer the question: can the investigators predict which adults with social anxiety disorder (SAD) will successfully respond to treatment? To answer this question, the investigators plan to recruit 190 adult participants who experience extreme forms of social...
What is the current status of trial NCT05683223?
This trial is currently recruiting. It is a NA study. The enrollment target is 240 participants. The study started on 2023-05-26. Estimated completion is 2027-06-30.
What conditions does trial NCT05683223 study?
This clinical trial studies the following conditions: Social Anxiety Disorder.
What interventions are being tested in trial NCT05683223?
The interventions under investigation include: Sertraline (DRUG), Group CBT for Social Anxiety Disorder (BEHAVIORAL), Individual CBT for Social Anxiety Disorder (BEHAVIORAL).
Who is sponsoring clinical trial NCT05683223?
This trial is sponsored by Boston University Charles River Campus, which has 104 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05683223 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Social Anxiety Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Validating an Autonomous Interactive Internet-Based Delivery of an Empirically Supported Cognitive Behavioral Therapy for Comorbidity
RECRUITING · NA
-
Individual Factors of CBT Underlying Success
RECRUITING · NA
-
Neurofeedback Enhanced Cognitive Reappraisal Training - Phase 4
RECRUITING · NA
-
Very Brief Exposure: Development of a Novel Exposure Modality for Social Anxiety Disorder in Transition-Age Youth
RECRUITING · NA
-
Targeting Social Function in Anxiety and Eating Disorders
RECRUITING · NA
-
Attention Bias Modification Training for Social Phobia (ABMSP)
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.